p53 aberration and TFE3 gene amplification may be predictors of adverse prognosis in epithelioid angiomyolipoma of the kidney

投稿日：

完全版を表示する

P53 Aberration and TFE3 Gene Amplification May Be Predictors of Adverse Prognosis in Epithelioid Angiomyolipoma of the Kidney

Summary of the Study

  • Epithelioid angiomyolipoma (EAML) is a rare renal tumor that is often misdiagnosed as renal cell carcinoma.
  • This study aimed to identify potential predictors of adverse prognosis in EAML.
  • The study included a total of 24 patients with EAML.
  • The researchers found that p53 aberration and TFE3 gene amplification were associated with adverse prognosis in EAML.
  • The findings suggest that p53 aberration and TFE3 gene amplification may be useful predictors of adverse prognosis in EAML.

Detailed Overview of the Study

Epithelioid angiomyolipoma (EAML) is a rare renal tumor that is often misdiagnosed as renal cell carcinoma. It is characterized by a variable degree of epithelial, smooth muscle, and fat components. The prognosis of EAML is generally favorable, but some cases may be associated with adverse outcomes. Therefore, it is important to identify potential predictors of adverse prognosis in EAML.

In this study, the researchers aimed to identify potential predictors of adverse prognosis in EAML. The study included a total of 24 patients with EAML who underwent radical or partial nephrectomy between January 2000 and December 2018. The researchers analyzed the clinicopathological features of the patients and performed immunohistochemical staining for p53 and TFE3.

The results of the study showed that p53 aberration and TFE3 gene amplification were associated with adverse prognosis in EAML. The researchers also found that the presence of epithelial component, tumor size, and lymph node metastasis were associated with adverse prognosis.

The findings of this study suggest that p53 aberration and TFE3 gene amplification may be useful predictors of adverse prognosis in EAML. Further studies are needed to confirm these findings and to determine the clinical implications of these findings.

  • B!